A phase I trial to examine the safety, tolerability, and pharmacokinetics of ASN100 in healthy volunteers
Latest Information Update: 13 Jun 2019
Price :
$35 *
At a glance
- Drugs ASN 100 (Primary)
- Indications Staphylococcal infections
- Focus Adverse reactions; First in man
- Sponsors Arsanis
- 28 May 2019 Results (n=52) published in the Antimicrobial Agents and Chemotherapy.
- 07 Oct 2018 Results presented at the IDWeek 2018
- 08 Oct 2017 Results of serum and lung pharmacokinetics of ASN100 presented at the IDWeek 2017